Posted by Michael Wonder on 09 May 2023
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies
9 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using belantamab mafodotin in the NHS in England.
Belantamab mafodotin is not recommended, within its marketing authorisation, for treating multiple myeloma in adults who have had 4 or more previous treatments and whose cancer is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 monoclonal antibody, and whose cancer progressed on the last treatment.
